Cabanib
Generic Name
Cabozantinib
Manufacturer
Beacon Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| cabanib 20 mg capsule | ৳ 120.00 | ৳ 1,200.00 |
Description
Overview of the medicine
Cabanib (Cabozantinib) is an oral multiple tyrosine kinase inhibitor used in the treatment of various cancers, including medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
Uses & Indications
Dosage
Adults
For Renal Cell Carcinoma and Hepatocellular Carcinoma: 60 mg orally once daily. For Medullary Thyroid Carcinoma: 140 mg orally once daily. Dosage adjustments (e.g., to 20 mg, 40 mg) may be necessary based on tolerability and adverse effects.
Elderly
No specific dose adjustment based on age alone, but monitor for adverse reactions.
Renal_impairment
No specific dose adjustment for mild to moderate renal impairment. Use with caution in severe renal impairment; dose reduction may be considered.
How to Take
Take orally, once daily. Do not take with food (at least 2 hours before or 1 hour after a meal). Swallow capsules whole; do not open or crush.
Mechanism of Action
Cabozantinib inhibits the activity of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR1, VEGFR2, VEGFR3, KIT, TRKB, FLT3, AXL, and RET. These kinases are involved in tumor growth, angiogenesis, and metastasis.
Pharmacokinetics
Onset
Not immediately applicable, therapeutic effects are observed over weeks.
Excretion
Mainly excreted in feces (approximately 80%), with a smaller amount in urine (approximately 15%).
Half life
Approximately 99 hours (effective half-life is longer due to slow elimination).
Absorption
Absorbed orally. Peak plasma concentrations are reached 2-4 hours post-dose. High-fat meal increases Cmax and AUC.
Metabolism
Extensively metabolized, primarily by CYP3A4, with minor contributions from CYP2C8 and CYP2C9.
Side Effects
Contraindications
- •Hypersensitivity to cabozantinib or any excipients.
- •Pregnancy (absolute contraindication due to embryofetal toxicity).
Drug Interactions
P-glycoprotein (P-gp) inhibitors/inducers
Potential for altered absorption; monitor closely.
Strong CYP3A4 Inducers (e.g., rifampin, phenytoin)
May decrease cabozantinib exposure; increase cabozantinib dose.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)
May increase cabozantinib exposure; reduce cabozantinib dose.
Storage
Store at room temperature (20°C to 25°C), away from moisture and heat. Keep out of reach of children.
Overdose
No specific antidote. Manage overdose with supportive care and close monitoring for adverse effects. Dose interruption or reduction may be necessary.
Pregnancy & Lactation
Contraindicated during pregnancy (Category D). Advise women of reproductive potential to use effective contraception. Discontinue breastfeeding during treatment and for at least 4 months after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months, refer to package insert.
Availability
Pharmacies, Hospitals
Approval Status
FDA approved
Patent Status
Patented, but generics might be available in some regions due to compulsory licensing or patent expiry for specific indications/countries
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
